Mashup Score: 1PubMed
Venetoclax-obinutuzumab with or without ibrutinib was superior to chemoimmunotherapy as first-line treatment in fit patients with CLL. (Funded by AbbVie and others; GAIA-CLL13 ClinicalTrials.gov number, NCT02950051; EudraCT number, 2015-004936-36.).
Randomized trial in NEJM of >900 CLL patient (without tp53 mutation) randomized to Ven-Obi, Ven-Obi-Ibr, chemo (with BR or FCR) or Ven-rituximab showed improved PFS at 3 years for the Obi containing arms vs chemo but not the Ven-Rituximab arm. There was no difference seen in OS. Patients with mutated IGVH did well in all groups without significant difference in outcomes.